Molecular response and clinical outcome after GO
. | Results of qualitative RT-PCR for PML-RARα* . | . | . | . | . | . | . | . | ||
---|---|---|---|---|---|---|---|---|---|---|
Patient no. . | 1st cycle . | 2nd cycle . | 3rd cycle . | No. GO cycles received . | Relapse/type . | Duration of molecular remission, mos. . | Successive therapies . | Outcome . | ||
1 | ND | Negative | Negative | 3 | No | 31+ | — | Alive in MR | ||
2 | Negative | Negative | Negative | 3 | No | 14+ | — | Alive in MR | ||
3 | Positive | Positive | — | 2 | Yes/morphologic | NE | MITOX, MITOX† | Alive in MR | ||
4 | Negative | Negative | Negative | 3 | Yes/molecular | 13 | GO†/MITOX + ARA-C | Alive in MR | ||
5 | Negative | Negative | Negative | 3 | Yes/morphologic | 6 | MITOX + ARA-C | Died of disease progression | ||
6 | ND | Negative | Negative | 3 | No | 7+ | — | Alive in MR | ||
7 | ND | ND | — | 2 | Yes/morphologic | NE | — | Died of disease progression | ||
8 | Negative | ND | Negative | 3 | Yes/molecular | 7 | MITOX + ARA-C | Alive in MR | ||
9 | ND | Negative | Negative | 3 | Yes/molecular | 8 | GO‡ | Alive in MR | ||
10 | ND | Negative | Negative | 3 | No | 19+ | — | Alive in MR | ||
11 | Negative | — | — | 1 | Yes/molecular | 6 | DLI | Alive in MR | ||
12 | ND | ND | Negative | 3 | No | 12+ | — | Alive in MR | ||
13 | ND | ND | Negative | 3 | No | 19+ | DLI | Alive in MR | ||
14 | ND | Positive | Negative | 3 | No | 15+ | — | Alive in MR | ||
15 | ND | Negative | Negative | 3 | Yes/molecular | 15 | — | Alive in MR | ||
16 | Negative | Negative | Negative | 3 | Yes/morphologic | 3 | ATO | Died of disease progression |
. | Results of qualitative RT-PCR for PML-RARα* . | . | . | . | . | . | . | . | ||
---|---|---|---|---|---|---|---|---|---|---|
Patient no. . | 1st cycle . | 2nd cycle . | 3rd cycle . | No. GO cycles received . | Relapse/type . | Duration of molecular remission, mos. . | Successive therapies . | Outcome . | ||
1 | ND | Negative | Negative | 3 | No | 31+ | — | Alive in MR | ||
2 | Negative | Negative | Negative | 3 | No | 14+ | — | Alive in MR | ||
3 | Positive | Positive | — | 2 | Yes/morphologic | NE | MITOX, MITOX† | Alive in MR | ||
4 | Negative | Negative | Negative | 3 | Yes/molecular | 13 | GO†/MITOX + ARA-C | Alive in MR | ||
5 | Negative | Negative | Negative | 3 | Yes/morphologic | 6 | MITOX + ARA-C | Died of disease progression | ||
6 | ND | Negative | Negative | 3 | No | 7+ | — | Alive in MR | ||
7 | ND | ND | — | 2 | Yes/morphologic | NE | — | Died of disease progression | ||
8 | Negative | ND | Negative | 3 | Yes/molecular | 7 | MITOX + ARA-C | Alive in MR | ||
9 | ND | Negative | Negative | 3 | Yes/molecular | 8 | GO‡ | Alive in MR | ||
10 | ND | Negative | Negative | 3 | No | 19+ | — | Alive in MR | ||
11 | Negative | — | — | 1 | Yes/molecular | 6 | DLI | Alive in MR | ||
12 | ND | ND | Negative | 3 | No | 12+ | — | Alive in MR | ||
13 | ND | ND | Negative | 3 | No | 19+ | DLI | Alive in MR | ||
14 | ND | Positive | Negative | 3 | No | 15+ | — | Alive in MR | ||
15 | ND | Negative | Negative | 3 | Yes/molecular | 15 | — | Alive in MR | ||
16 | Negative | Negative | Negative | 3 | Yes/morphologic | 3 | ATO | Died of disease progression |
ND indicates not done; MR, molecular remision; NE, not evaluable; ATO, arsenic trioxide; DLI, donor lymphocyte infusion; and —, patient did not receive this treatment. See Table 1 footnote for other abbreviations.
In 4 cases, the material collected after the second GO dose was insufficient for RT-PCR analysis.
Patient received 3 additional GO doses.
Patient received 4 additional GO doses.